

36. (New) A coated pharmaceutical composition as claimed in claim 31, wherein the composition is a delayed-release composition.

37. (New) A coated pharmaceutical composition as claimed in claim 31, wherein the composition is acid-resistant.

38. (New) A coated pharmaceutical composition as claimed in claim 31, wherein the composition is an enteric composition.

39. (New) A coated pharmaceutical composition as claimed in claim 31, wherein the coating comprises cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate or one or more anionic polymers of methacrylic acid and methyl methacrylate.

40. (New) A coated pharmaceutical composition as claimed in claim 38, wherein the coating comprises cellulose acetate phthalate, polyvinyl acetate phthalate, hydroxypropylmethylcellulose phthalate or one or more anionic polymers of methacrylic acid and methyl methacrylate.

Remarks


Applicants have added a first paragraph of the specification to recite the domestic priority information for this application. Claims 1-30 have been canceled. New claims 31-40 are supported in the specification, particularly in original claims 1-4 and 11 and in the description at page 7, lines 8-16.

If there is any fee due in connection with the filing of this Preliminary Amendment, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: June 27, 2003

By: 
Steven J. Scott
Reg. No. 43,911